Navigation Links
Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
Date:8/22/2008

9,395 Women Enrolled in Trial Sponsored by Medical Research Council

LEXINGTON, Mass., Aug. 22 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today the completion of enrollment in Protocol MDP 301, a Phase III clinical trial of PRO 2000, the Company's candidate vaginal microbicide for the prevention of HIV and other sexually transmitted infections. The trial is sponsored by the United Kingdom's Medical Research Council (MRC) and conducted by the Microbicides Development Programme (MDP), an international partnership of researchers established to develop microbicides for the prevention of HIV transmission. This trial enrolled 9,395 women at clinics in South Africa, Tanzania, Uganda, and Zambia. Results from this trial are expected to be available by the end of 2009.

This is the second large trial testing the safety and effectiveness of the 0.5% dose of PRO 2000 and the largest trial of any microbicide to date. In July 2007, enrollment of 3,100 women was completed in Protocol HPTN 035 sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Results from the HPTN 035 trial are expected to be available by early 2009.

"The completion of enrollment in this trial marks a significant milestone for Indevus, our shareholders and for women who may benefit from a product that provides a female-controlled option for HIV and STD prevention," said Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "We have now completed enrollment in two pivotal trials with over 12,000 women participating. If the trials are successful, we expect to be in a position to file marketing applications with regulatory authorities, in
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Submission of New Drug Application
3. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
4. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
5. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
6. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned ... market share and grab a foothold in the hydroponic, hemp ... capabilities and a presence in the sector, and recently partnering ... growth of hemp and medical marijuana, iMD is committing to ...
(Date:1/23/2015)... 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... adsorber to reduce deadly inflammation in critically-ill and ... net of transaction costs, in non-dilutive funding as ... Certificate Transfer Program sponsored by the New Jersey ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... Jan. 26, 2012 Masimo (NASDAQ: MASI ... year financial results for the period ended December 31, 2011, after ... review the results will begin at 1:30 p.m. PT (4:30 p.m. ... Executive Officer, and Mark P. de Raad, Executive Vice President and ...
... Dr. Ira J. Haimowitz, Executive Vice President, Group Director, Intelligence ... at the eMarketing University for Brand Managers, a symposium at ... 2012. The symposium is a full-day course designed ... tactics into their marketing mix. Dr. Haimowitz will be presenting ...
Cached Medicine Technology:Masimo to Report Fourth Quarter and Full Year 2011 Financial Results After Market Close on February 14, 2012 2Masimo to Report Fourth Quarter and Full Year 2011 Financial Results After Market Close on February 14, 2012 3Ira Haimowitz, PhD, EVP, at The CementBloc, to Present on Best Practices in iPad Interactive Selling at 11th Annual ePharma Summit™ 2
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
(Date:1/22/2015)... Mass. (PRWEB) January 22, 2015 EBSCO ... (AMA) are expanding their relationship in an effort to ... around the world. While EBSCO has long made AMA journals ... a sales agent for The JAMA Network. , ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... LANSING, Mich., March 27 Accident Fund Insurance,Company ... its,outstanding achievements in creating a safe work environment. ... experiencing one lost-time,incident, when in 2006 the Michigan ... employees unable to work. Clark Construction,received the Gold ...
... Support Health Plans Next Generation of Care Management ... and Special Need Populations, SAN ANTONIO and AUBURN, ... only locally owned and operated,non-profit HMO, announced today that ... to support its next,generation of care management programs sponsored ...
... By Tobacco Advertising and Find It,Easy to Buy Cigarettes, ... against tobacco on April 2 as they join thousands ... Day, sponsored by the,Campaign for Tobacco-Free Kids. Hundreds of ... local events, go to http://www.kickbuttsday.org/events )., This ...
... Tobacco Advertising and Find It,Easy to Buy Cigarettes, ... tobacco on April 2 as they join thousands of ... sponsored by the,Campaign for Tobacco-Free Kids. Hundreds of events ... events, go to, http://www.kickbuttsday.org/events )., This year, Kick ...
... Proposed Bush FY 2009 Budget Slashes Nursing Home ... Medicare Cuts Place Greater,Pressure on State Medicaid Program ... National and state,front line caregivers voiced opposition ... care for Michigan seniors contained in the,Bush Administration,s ...
... properties of bitter melon, a vegetable and traditional Chinese ... 2 diabetes. , Teams from the Garvan Institute of ... pulped roughly a tonne of fresh bitter melon and ... all appear to activate the enzyme AMPK, a protein ...
Cached Medicine News:Health News:Accident Fund Recognizes Clark Construction Co. for 2 Million Hours without a Lost-Time Injury 2Health News:Community First Health Plans Selects TCS Healthcare Technologies' Care Management Software System 2Health News:Community First Health Plans Selects TCS Healthcare Technologies' Care Management Software System 3Health News:California Kids 'Kick Butts' on April 2 2Health News:California Kids 'Kick Butts' on April 2 3Health News:Georgia Kids 'Kick Butts' on April 2 2Health News:Georgia Kids 'Kick Butts' on April 2 3Health News:National, State Front Line Caregivers Warn About $64 Million Cut to Medicare Funding for Care of Michigan Seniors 2Health News:National, State Front Line Caregivers Warn About $64 Million Cut to Medicare Funding for Care of Michigan Seniors 3Health News:National, State Front Line Caregivers Warn About $64 Million Cut to Medicare Funding for Care of Michigan Seniors 4Health News:A ton of bitter melon produces sweet results for diabetes 2
... the 17 million echocardiograms performed annually ... DEFINITY increases the power of echocardiography, ... than with echo alone. As a ... for many patientsby illuminating the heart, ...
... Launched in 1996, VISIPAQUE is the only ... With an osmolality equal to that of blood, ... VISIPAQUE is also the only contrast medium formulated ... to blood. In 1997, VISIPAQUE received FDA approval ...
The Pinn-ACL Guide can be used to create tibial tunnels of known lengths with a variable angle adjustment of 35 to 60 degrees with the use of a,graduated pin-sleeve....
... Padgett's commitment to quality and innovation has ... product developments: The Model C is an ... required for instruments in burn care surgery. ... constructed with the same dedication to quality, ...
Medicine Products: